Loading…
Serina Therapeutics, Inc. is projected to rise to $2.46 by 2027, a +15% move from its current price of $2.14. SER is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $2.04 | $2.14 | $2.25 | +0.09% |
| Jul 15 | $2.00 | $2.14 | $2.29 | +0.18% |
| Jul 16 | $1.97 | $2.15 | $2.33 | +0.28% |
| Jul 17 | $1.95 | $2.15 | $2.36 | +0.37% |
| Jul 18 | $1.93 | $2.15 | $2.39 | +0.46% |
| Jul 19 | $1.91 | $2.15 | $2.42 | +0.55% |
| Jul 20 | $1.90 | $2.15 | $2.45 | +0.65% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.90 | $2.15 | $2.45 | +0.65% |
| Week 2 | $1.81 | $2.17 | $2.59 | +1.30% |
| Week 3 | $1.75 | $2.18 | $2.72 | +1.95% |
| Week 4 | $1.70 | $2.20 | $2.83 | +2.62% |
| Week 5 | $1.66 | $2.21 | $2.94 | +3.28% |
| Week 6 | $1.63 | $2.22 | $3.04 | +3.95% |
| Week 7 | $1.60 | $2.24 | $3.13 | +4.62% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial.
In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
Serina Therapeutics, Inc. trades under the symbol SER and has a current price of $2.20 with a market capitalization of $32.99M. It is ranked 4748 in market cap terms. The stock is positioned in the biotechnology/healthcare sector and carries a modest near-term price profile given its micro-cap status.
A major floor 40.2% below — a decisive break under it would weaken the trend.
The nearest floor, 18.7% below — buyers have tended to step in here.
Price is pressing into resistance (2.8% away) — a breakout level to watch.
A major ceiling 47.2% above — clearing it would confirm fresh momentum.
Key SER support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SER market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.09 | Buy | $2.09 | Buy |
| MA 10 | $2.00 | Buy | $2.03 | Buy |
| MA 20 | $1.96 | Buy | $1.97 | Buy |
| MA 50 | $1.85 | Buy | $1.93 | Buy |
| MA 100 | $1.88 | Buy | $2.10 | Buy |
| MA 200 | $2.77 | Sell | $2.78 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.10 | Neutral |
| Stoch RSI (14) | 69.48 | Neutral |
| CCI (20) | 129.43 | Buy |
| Williams %R (14) | -15.38 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 11.46 | Buy |
| Bollinger %B (20,2) | 0.89 | Neutral |
| Stochastic %K (14) | 84.62 | Sell |
| TRIX (15) | 0.32 | Buy |
| Awesome (5,34) | 0.18 | Buy |
| Ultimate (7,14,28) | 59.17 | Neutral |
| Momentum (10) | 0.32 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 2.18 | Sell |
| ADX (14) | 9.96 | Neutral |
| ATR (14) | 0.09 | Info |
The near-term technical picture is bullish in tone. The RSI14 sits at 60, and the stock’s momentum edges higher alongside a bullish tilt. The short-term moving averages show the price tracing above a $1.85 50-day simple moving average, while the 200-day average sits at $2.79.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.28 | $2.14 | $3.30 | 0% | Neutral | |
| $1.82 | $2.46 | $3.59 | +15% | Neutral | |
| $1.66 | $2.36 | $3.65 | +10% | Neutral | |
| $1.58 | $2.36 | $3.82 | +10% | Neutral | |
| $1.30 | $2.03 | $3.40 | -5% | Neutral | |
| $1.54 | $2.49 | $4.31 | +16% | Neutral | |
| $1.93 | $3.22 | $5.75 | +51% | Bullish | |
| $1.86 | $3.23 | $5.91 | +51% | Bullish | |
| $1.90 | $3.41 | $6.39 | +59% | Bullish | |
| $1.80 | $3.33 | $6.37 | +56% | Bullish | |
| $2.23 | $4.81 | $10.07 | +125% | Bullish | |
| $3.44 | $7.65 | $17.60 | +258% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.28 | $2.14 | $2.61 | +0.00% |
| August 2026 | $1.88 | $2.27 | $2.84 | +6.01% |
| September 2026 | $1.91 | $2.33 | $2.97 | +2.61% |
| October 2026 | $1.83 | $2.26 | $2.93 | -2.98% |
| November 2026 | $1.86 | $2.31 | $3.04 | +2.42% |
| December 2026 | $1.98 | $2.48 | $3.30 | +7.24% |
Click any year to see its month-by-month SER forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, SER is projected to trade between $1.28 and $3.30, averaging $2.14 — a potential gain of 0% from today's $2.14. A consolidation phase looks the most probable path here.
Serina Therapeutics, Inc.'s 2027 outlook centres on $2.46, within a $1.82 to $3.59 range. That is up +15% on the projected 2026 average. That marks a +15% change versus current levels. Price action looks broadly range-bound.
By 2028, SER could reach as high as $3.65, with a base case around $2.36 and support toward $1.66 — roughly +10% from $2.14. A consolidation phase looks the most probable path here.
Expect SER to range from $1.58 to $3.82 through 2029. The $2.36 average target implies a +10% move from current prices. That is up 0% on the projected 2028 average. Price action looks broadly range-bound.
The SER price prediction for 2030 points to an average of $2.03 (low $1.30, high $3.40) — a potential decline of -5% on today's $2.14. A consolidation phase looks the most probable path here.
In 2031, SER is projected to trade between $1.54 and $4.31, averaging $2.49 — a potential gain of +16% from today's $2.14. That is up +23% on the projected 2030 average. Price action looks broadly range-bound.
Serina Therapeutics, Inc.'s 2032 outlook centres on $3.22, within a $1.93 to $5.75 range. That is up +30% on the projected 2031 average. That marks a +51% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, SER could reach as high as $5.91, with a base case around $3.23 and support toward $1.86 — roughly +51% from $2.14. Momentum favours further upside here.
Expect SER to range from $1.90 to $6.39 through 2034. The $3.41 average target implies a +59% move from current prices. That is up +6% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The SER price prediction for 2035 points to an average of $3.33 (low $1.80, high $6.37) — a potential gain of +56% on today's $2.14. Momentum favours further upside here.
In 2040, SER is projected to trade between $2.23 and $10.07, averaging $4.81 — a potential gain of +125% from today's $2.14. That is up +45% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Serina Therapeutics, Inc.'s 2050 outlook centres on $7.65, within a $3.44 to $17.60 range. That is up +59% on the projected 2040 average. That marks a +258% change versus current levels. Momentum favours further upside here.
Investing $1,000 in SER today (≈ 467.28972 SER) could be worth
$3,576.21
+$2,576.21 (+258%) by 2050 · US Dollar
Based on the average projected SER price of $7.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SERwould be worth at today's price.
$1,000 invested in SER on Jul 10, 2025 (≈ 169.606516 SER) would be worth
$362.96
-$637.04 (-63.7%) today · 0.36× · US Dollar
Based on a SER entry price of $5.9 vs. today's $2.14.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.9 | $1,126.32 | +12.6% |
| 1 month ago | $1.74 | $1,229.89 | +23.0% |
| 3 months ago | $1.98 | $1,080.81 | +8.1% |
| 6 months ago | $2.47 | $866.4 | -13.4% |
| 1 year ago | $5.9 | $362.96 | -63.7% |
| All time (5.0y) ago | $52.14 | $41.04 | -95.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SER forecast.
Our base-case forecast reaches $4.30 around 2040.
Implied market cap at $4.30: $64.49M
Across its multi-year forecast, SER shows an upward path with a rising average price later in the horizon. The 2030 estimate has an average of $2.06 with a negative ROI of -6.3% (min $1.31, max $3.49). The 2040 forecast improves to an average of $4.98 with a 126.3% ROI (min $2.25, max $10.54), and the 2050 forecast projects an average of $7.92 with a 259.8% ROI (min $3.56, max $18.21).
Sentiment improves from Neutral in 2030 to Bullish in 2040 and 2050, reflecting a stronger long-run outlook albeit with substantial variability across years. These figures illustrate potential upside alongside notable risk, and they are estimates, not guarantees.
Tap a question to reveal the answer.
Min $1.28, Avg $2.20, Max $3.42, ROI 0, Sentiment NEUTRAL.
Forecasts show a broad range of outcomes with an average price around $2.20 in 2026 and rising to $7.92 by 2050, with ROIs up to 259.8% in 2050 and 126.3% in 2040, but results vary by year and carry risk.
2030 forecast has Avg $2.06, Min $1.31, Max $3.49 and ROI -6.3%, so a $5 target is not indicated by the 2030 projection.
Avg $4.98, Min $2.25, Max $10.54, ROI 126.3, Sentiment BULLISH.
Current price $2.20; Market cap $32.99M.
Serina Therapeutics, Inc. Community Discussion
0Share your Serina Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.